Managing diabetic foot in times of COVID-19: time to put the best 'foot' forward.

Avica Atri, Chaithanya Murthy Kocherlakota, Riddhi Dasgupta
Author Information
  1. Avica Atri: Christian Medical College & Hospital, Vellore, Tamil Nadu India.
  2. Chaithanya Murthy Kocherlakota: Department of Diabetology, Dr. Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu India.
  3. Riddhi Dasgupta: Department of Endocrinology, NM Hospitals, Kolkata, West Bengal 700008 India. ORCID

Abstract

INTRODUCTION: The COVID-19 pandemic has had an unparalleled impact on the socio-economic and healthcare structure of India. Due to our large populations of diabetic patients, who have an increased risk of worse outcomes with COVID-19 infection, it is of utmost public health importance to analyse the relationship between the two. The aim of our review was to analyse the possible relationship between COVID-19 infection and DFUs, which are a fairly common, yet serious complication in diabetic patients, as well as their management, under the given changing circumstances.
METHODOLOGY: An extensive review of related educational articles was analysed from various databases.
RESULTS: The two main pathogenic mechanisms described in COVID-19 infection are a cytokine storm (causing ARDS) as well as an acquired coagulopathy, with widespread thrombosis. DFUs are associated with an underlying peripheral neuropathy, a chronic low-grade inflammatory state and peripheral arterial disease, which lead to chronic non-healing ulcers. Similarities seen in the pathogenic mechanisms of these two conditions make a bidirectional relationship highly plausible.
CONCLUSION: Due to the disruptions in the healthcare system brought on by the COVID-19 pandemic, changes in practice to a telehealth-driven approach, with emphasis on homecare and community clinics, need to be adopted, to ensure best possible care to patients with DFUs, in order to reduce their risk of DFU-related complications and need for hospitalization.

Keywords

References

  1. Biomedicine (Taipei). 2015 Dec;5(4):22 [PMID: 26615539]
  2. Am J Respir Crit Care Med. 2005 Apr 15;171(8):850-7 [PMID: 15657466]
  3. Diabetes Metab Syndr. 2020 Jul - Aug;14(4):273-276 [PMID: 32283497]
  4. Pharmacol Res. 2017 Nov;125(Pt A):21-38 [PMID: 28619367]
  5. J Thromb Haemost. 2020 Apr;18(4):844-847 [PMID: 32073213]
  6. Int J Low Extrem Wounds. 2020 Jun;19(2):111 [PMID: 32320324]
  7. Diabetologia. 1999 Nov;42(11):1308-13 [PMID: 10550414]
  8. Future Microbiol. 2009 Nov;4(9):1151-65 [PMID: 19895218]
  9. J Virol. 2020 Mar 17;94(7): [PMID: 31996437]
  10. Case Rep Endocrinol. 2012;2012:165056 [PMID: 23304571]
  11. J Vasc Surg. 2020 Dec;72(6):1864-1872 [PMID: 32360679]
  12. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  13. Monaldi Arch Chest Dis. 2020 Apr 10;90(1): [PMID: 32290644]
  14. Eur Respir J. 2020 May 14;55(5): [PMID: 32217650]
  15. J Am Soc Nephrol. 2008 Mar;19(3):433-42 [PMID: 18256353]
  16. Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S62-5 [PMID: 18393327]
  17. J Vasc Surg. 2002 Mar;35(3):501-5 [PMID: 11877698]
  18. Rev Endocr Metab Disord. 2019 Jun;20(2):207-217 [PMID: 30937614]
  19. Clin Infect Dis. 2012 Jun;54(12):e132-73 [PMID: 22619242]
  20. Front Immunol. 2019 May 10;10:1071 [PMID: 31134099]
  21. Lancet. 2005 Nov 12;366(9498):1736-43 [PMID: 16291068]
  22. Curr Diab Rep. 2016 Mar;16(3):29 [PMID: 26897744]
  23. Cytokine Growth Factor Rev. 2020 Jun;53:66-70 [PMID: 32418715]
  24. J Diabetes Complications. 2020 Sep;34(9):107622 [PMID: 32419767]
  25. Diabet Med. 2016 Nov;33(11):1493-1498 [PMID: 26666583]
  26. Front Endocrinol (Lausanne). 2017 May 02;8:89 [PMID: 28512447]
  27. J Thromb Thrombolysis. 2020 Jul;50(1):54-67 [PMID: 32415579]
  28. Wounds. 2020 Jul;32(7):178-185 [PMID: 32335520]
  29. Diabet Med. 2012 Jan;29(1):43-9 [PMID: 22050401]
  30. J Diabetes Investig. 2018 Sep;9(5):1016-1018 [PMID: 29277966]
  31. Diabetes. 2007 Dec;56(12):2997-3005 [PMID: 17720896]
  32. J Diabetes Sci Technol. 2011 Nov 01;5(6):1591-5 [PMID: 22226282]
  33. Diabetes Care. 1999 Jul;22(7):1029-35 [PMID: 10388962]
  34. Diabet Foot Ankle. 2013 May 21;4: [PMID: 23705058]
  35. Cytokine Growth Factor Rev. 2020 Jun;53:25-32 [PMID: 32446778]
  36. J Am Podiatr Med Assoc. 2023 Mar-Apr;113(2): [PMID: 32208983]
  37. Cell. 2020 May 14;181(4):905-913.e7 [PMID: 32333836]
  38. Lancet Diabetes Endocrinol. 2020 Jul;8(7):570 [PMID: 32445630]
  39. Cytokine Growth Factor Rev. 2020 Aug;54:62-75 [PMID: 32513566]
  40. Int J Low Extrem Wounds. 2007 Mar;6(1):37-53 [PMID: 17344201]

Word Cloud

Created with Highcharts 10.0.0COVID-19diabeticpatientsinfectionrelationshiptwoDFUsperipheralpandemichealthcareDueriskanalysereviewpossiblewellpathogenicmechanismsstormneuropathychroniculcersneedbestfootDiabeticINTRODUCTION:unparalleledimpactsocio-economicstructureIndialargepopulationsincreasedworseoutcomesutmostpublichealthimportanceaimfairlycommonyetseriouscomplicationmanagementgivenchangingcircumstancesMETHODOLOGY:extensiverelatededucationalarticlesanalysedvariousdatabasesRESULTS:maindescribedcytokinecausingARDSacquiredcoagulopathywidespreadthrombosisassociatedunderlyinglow-gradeinflammatorystatearterialdiseaseleadnon-healingSimilaritiesseenconditionsmakebidirectionalhighlyplausibleCONCLUSION:disruptionssystembroughtchangespracticetelehealth-drivenapproachemphasishomecarecommunityclinicsadoptedensurecareorderreduceDFU-relatedcomplicationshospitalizationManagingtimesCOVID-19:timeput'foot'forwardCytokineDFUDPNIschemia

Similar Articles

Cited By